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Effectiveness of Anti-TNFa for Crohn Disease:
Research in a Pediatric Learning Health System
WHAT’S KNOWN ON THIS SUBJECT: Studies on adult patients who
have Crohn disease have shown a comparative benefit of anti-
TNFa versus placebo and thiopurines. These same studies have
not been done in children, because of time, cost, and ethical
(withholding an efficacious treatment) challenges.
WHAT THIS STUDY ADDS: Anti-TNFa therapy administered in routine
practice to children with Crohn disease was more effective than
usual care at achieving clinical and corticosteroid-free remission.
Using data from the ImproveCareNow learning health system for
observational research is feasible and produces valuable evidence.
abstract
OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning
health system in the nation and started as a quality improvement col-
laborative. To test the feasibility and validity of using ICN data for clinical
research, we evaluated the effectiveness of anti-tumor necrosis factor-a
(anti-TNFa) agents in the management of pediatric Crohn disease (CD).
METHODS: Data were collected in 35 pediatric gastroenterology prac-
tices (April 2007 to March 2012) and analyzed as a sequence of non-
randomized trials. Patients who had moderate to severe CD were
classified as initiators or non-initiators of anti-TNFa therapy. Among
4130 patients who had pediatric CD, 603 were new users and 1211
were receiving anti-TNFa therapy on entry into ICN.
RESULTS: During a 26-week follow-up period, rate ratios obtained from
Cox proportional hazards models, adjusting for patient and disease
characteristics and concurrent medications, were 1.53 (95% confi-
dence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI,
1.33–2.29) for corticosteroid-free remission. The rate ratio for
corticosteroid-free remission was comparable to the estimate pro-
duced by the adult SONIC study, which was a randomized controlled
trial on the efficacy of anti-TNFa therapy. The number needed to
treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95%
CI, 3.4–10.0) for corticosteroid-free remission.
CONCLUSIONS: In routine pediatric gastroenterology practice settings,
anti-TNFa therapy was effective at achieving clinical and corticosteroid-
free remission for patients who had Crohn disease. Using data from
the ICN learning health system for the purpose of observational re-
search is feasible and produces valuable new knowledge. Pediatrics
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Over thelastseveraldecades, therapeutic
advances in the treatment of pediatric
Crohn disease (CD) have included the
widespread use of immunomodulators
such as 6-mercaptopurine, azathioprine,
and methotrexate.1–3 More recently, the
anti-tumor necrosis factor a (anti-TNFa)
biological agents (eg, infliximab and
adalimumab) have been adopted as
a treatment of moderate to severe pe-
diatric CD.4 Although several studies on
adult patients who have CD have shown
a comparative benefit of anti-TNFa ver-
sus placebo5 and thiopurines,6 these
same studies have not been done in
children because of practical (time and
cost) and ethical (withholding an effica-
cious treatment) challenges.
The cost of anti-TNFa is in the range of
tens of thousands of dollars per year,
and the long-term direct and indirect
costs are substantial.7 Administration of
anti-TNFa has been associated with se-
rious infections, hepatic T-cell lym-
phomas, systemic lupus, and blood
disorders.8 Variation in themanagement
of pediatric patientswho have CD results
in part from a paucity of evidence on
how to best treat patients who have this
disorder.9–11 The costs, risks, and treat-
ment variability of anti-TNFa therapy are
key reasons it was selected as 1 of the
Institute of Medicine’s top 25 compara-
tive effectiveness research priorities.12
To address the lack of information on the
effectiveness of anti-TNFa therapy for
moderate to severe pediatric CD, we
conducted a study to evaluate use of
these agents to induce remission among
children managed in pediatric gastro-
enterology practices. Similar to prag-
matic clinical trials, which assess the
effectiveness of therapies in unselected
patients,13 our study contrasted initia-
tion of biologic therapy among pediatric
patients who hadmoderate to severe CD
with usual care, which may involve any
combination of thiopurines, methotrex-
ate, corticosteroids, 5-aminosalicylates,
nutrition therapy, and surgery.
The studywas done in ImproveCareNow
(ICN), which started as a quality im-
provement collaborative and is be-
coming a national, distributed learning
health system. A learning health system
is organized around communities of
patients, clinicians, and researchers
who work together to purposefully in-
tegrate knowledge generation (re-
search) with knowledge dissemination
and implementationat thepoint-of-care
(quality improvement).14–19
ICN has included a chronic disease
registry since 2007. Initially, it was used
expressly for quality improvement. We
sought to test the feasibility and validity
of using these data for comparative ef-
fectiveness research. In addition to
estimating treatment effects, we con-
trasted our results with those reported
in 2 controlled trials: an anti-TNFa effi-
cacy study done with pediatric patients
(the REACH study4) and a comparative
study of anti-TNFa versus thiopurines




ICN was established in 2007 to improve
the health and health care of children
who have inflammatory bowel disease
(IBD).20,21 Participating pediatric gastro-
enterology practices enrolled patients in
an IBD registry, collected data at each
outpatient visit, conducted quality im-
provement activities, and participated in
research. Although sites worked to
provide highly reliable care through the
use of quality improvement methodol-
ogy adapted to local circumstances,
specific therapeutic choices were at the
discretion of physicians.
We created a research dataset from the
ICN registry by encrypting patient, phy-
sician, and practice identifiers and
offsetting dates by a patient-specific
randomly generated constant. The
Children’s Hospital of Philadelphia’s
Institutional Review Board deemed this
research exempt from continuing re-
view. The registry comprised longitudi-
nal records of clinical care and health
status collected during outpatient en-
counters and entered via a web-portal
into a central database. Data elements
included symptoms, results of physical
examinations, laboratory values, phy-
sician assessments, and prescribed
therapies. To standardize data collec-
tion, all sites were trained in the use of
the case report form. Select data issues
were reviewed at semi-annual in-person
meetings, monthly webinars, and via
listserv.
This study used ICN registry data col-
lected from April 2007 to March 2012.
A total of 35 pediatric gastroenterology
practices enrolled 6402 patients who had
IBD; of these, there were 4130 (65%) pa-
tientswhohadCDwhomade20 456visits.
Disease Activity
For each visit, clinicians recorded the
components of the Short Pediatric Crohn’s
Disease Activity Index (sPCDAI)22 and a
Physician Global Assessment rating of
disease severity (from 1 [inactive] to 4
[severe disease]). The sPCDAI used 6 of
the 11 components from the full PCDAI,23
including abdominal pain, stools, weight
loss, abdominal examination, extra-
intestinal manifestations, and general
well-being. The sPCDAI has comparable
discriminatory accuracy for categorizing
disease severity as the full PCDAI.22 Based
on the scoring conventions for the full
PCDAI, we defined moderate to severe
disease as a sPCDAI score $30, and
clinical remission as a score ,10. A
remission was considered corticosteroid-
free if a visit satisfied the clinical re-
mission criterion and the patient was not
takingoral corticosteroids at anydose.We
did not evaluate whether corticosteroid-
free remission was sustained.
Missing Data
Across the full dataset 8% of the sPCDAI
components were missing; 41% of visits
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had at least 1 missing component. To
address this problem, we implemented
multiple imputation (MI) using the SAS
procedure MI (SAS Institute, Inc, Cary,
NC). MI provides a range of reasonable
predictions for missing data. Inferences
obtained from multiply imputed data
account for both the missing data and
the uncertainty of the imputations.24–26
We implemented MI by creating 100
replicates of the dataset. The imputa-
tionprocedurefit a discriminantmodel,
which is appropriate for categorical
data such as the sPCDAI components.27
The independent variables in the dis-
criminant models were age, gender,
race (white, black, other), disease
phenotype (inflammatory, stricturing,
or penetrating), disease location (il-
eum, colon, and upper tract), con-
current medications (thiopurines,
methotrexate, 5-aminosalicylates, and
oral corticosteroids), Physician Global
Assessment of disease severity, prac-
tice site, and duration of disease. Once
missing components were imputed, we
computed the sPCDAI score. The trials
were formed and statistical models
run separately for each replicate, and
then results were pooled to obtain
single treatment estimates.
Trial Formation
We conceptualized the registry dataset
as a sequence of nonrandomized trials
in which anti-TNFa therapy was initi-
ated or not initiated.28 This sequential-
trials strategy allows a patient to
contribute .1 trial to the analysis,
which makes greatest use of avail-
able data.28,29 To be eligible as a first
visit in an initiator trial (ie, the base-
line visit), the patient had to be a new
user of anti-TNFa (either infliximab or
adalimumab) therapy. All visits made
by patients who never used biologic
therapy were potential non-initiator
baseline visits. Among users of bi-
ologic therapy, visits that occurred
before the start of biologic initiation
were potential starting points for non-
initiator trials.
Eligibility criteria for baseline visits for
all trials were age ,21 years and
moderate to severe disease severity
(sPCDAI score $30). Trials also in-
cluded a visit during the follow-up pe-
riod, which began at 2 weeks and
concluded at 26 or 52 weeks, and at
least 1 visit before the start of the trial.
We applied the trial selection criteria to
the 100 replicates of the dataset. Be-
cause some of the sPCDAI components
were imputed by using MI, the sPCDAI
values varied across replicates; thus,
trials could meet the inclusion criteria
of sPCDAI $30 in some but not other
replicates. The number of trials ranged
from 232 to 252 per replicate, with
amean of 241 for initiators, and 1147 to
1210 per replicate, with a mean of 1182
for non-initiators. Across the 100 rep-
licates, patients contributed 1.9 trials
on average.
Statistical Analyses
Outcomes for trials (clinical remis-
sion or corticosteroid-free remission)
were evaluated regardless of whether
patients subsequently altered ther-
apy. This approach makes use of the
intention-to-treat principle. We con-
ducted bivariate analyses to test the
comparability between initiator and
non-initiator trials on patient, disease,
and pharmacological treatment char-
acteristicsmeasuredat baseline. These
were implemented with logistic (cate-
gorical covariates) or linear (continu-
ous covariates) regressionmodels that
regressed type of trial (initiator versus
non-initiator) on 1 covariate and ob-
tained robust variance estimates, ac-
counting for clustering of trials within
a patient, for the differences in pro-
portions or means.
We computed the unadjusted proba-
bility of achieving remission during 26
or 52 weeks of follow-up. We adjusted
the probability of achieving remission
by using the generalized estimating
equation (GEE), clustering on patients,
with a logit link function, and adjusted
for patient age in years, gender (male,
female), race (white, black, other), dis-
easephenotype(inflammatory,stricturing,
penetrating), location of disease (il-
eum, colon, upper tract; all yes/no
indicators), time since CD diagnosis
(,1 year vs $1 year), and medica-
tion use (thiopurines, methotrexate,
5-aminosalicylates, and corticosteroids;
all yes/no indicators).
We estimated rate ratios by fitting a Cox
proportional hazards model, with time
since the start of the trial as the time
variable, and adjusted for the cova-
riates used in the GEEmodels. Separate
models were fit with 26- and 52-week
durations of follow-up.
To evaluate the timing of the effect of
biologics on induction of remission, we
plotted the cumulative probability of
remission and corticosteroid-free re-
mission as a function of time. We esti-
mated the cumulative probability of the
outcomes by week of follow-up for the
100 imputed replicates and averaged
these values to create the plots.
To estimate a number needed to treat
(NNT), we extended the trials to include
a 26-week pre-trial observation period.
This longitudinal analysis contrasted
the within-subjects pre–post change
between the 2 treatment groups. We fit
the generalized estimating equation,
clustering on patient, and regressed
the outcome on covariates and a 4-
category variable for treatment group
(initiator or non-initiator) by time pe-
riod (pre or post). The treatment effect
estimate contrasted the average trial-
level probability of remission from the
pre- to the post-period in the initiator
versus non-initiator groups. The NNT
was computed as the reciprocal of the
absolute percentage difference be-
tween the 2 groups30; we also com-
puted 95% confidence intervals (CI) for
the NNTs.31
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Some trials were censored at their last
visit because the treatment outcome
was not achieved during the obser-
vation period. Among these right-
censored trials, we identified those
with a visit 27 to 52weeks after the start
of the trial andused linear interpolation
to assign a sPCDAI score at 26 weeks
and then re-estimated treatment
effects. We also re-estimated treatment
effects using the single-item Physician
Global Assessment, which was present
for 96% of pediatric CD visits.
Comparison With REACH and SONIC
We applied the REACH selection criteria
to initiator trials,4 which involved
restricting the sample to those who
started anti-TNFa .3 months after di-
agnosis and were receiving thio-
purines and/or methotrexate at the
time of trial initiation. Although REACH
assessed remission at 10 weeks, we
allowed assessment to occur as late as
16 weeks to account for variation in
visit frequency.
We reanalyzed the SONIC study of adult
CD patients6 by combining its anti-TNFa
treatment arms (anti-TNFa only and
anti-TNFa with thiopurine), computing
the 26-week corticosteroid-free re-
mission rate, and estimating a rate
ratio using the thiopurine-only group
as the referent. We contrasted these
results with our study’s estimates.
RESULTS
Among the pediatric patients who had
CD in our sample, 1814 received anti-
TNFa therapy, and of these, 603 started
therapy during the time of the study.
There were 2316 patients who never
used anti-TNFa therapy.
Patient and disease characteristics and
concurrent medications at the baseline
visit of trials are shown in Table 1. Non-
initiator trials were more likely to begin
with thiopurines, 5-aminosalicylates,
and corticosteroids. Physicians rated di-
sease severity as higher for the initiator
trials, despite sPCDAI scores compa-
rable to the non-initiator trials.
By 26 weeks, initiator trials had a 54.4%
chance of achieving remission, whereas
non-initiators had a 41.2% chance
(Table 2). Also, by 26 weeks, initiators
had a 47.3% chance of achieving
corticosteroid-free remission vs 31.2%
for non-initiators. Adjusting for patient
and disease characteristics and base-
line medications produced comparable
remission rate estimates to unadjusted
analyses.
The remission rate ratios for 26 and 52
weeks of follow-up were similar in un-
adjusted and adjusted analyses (Table 3).
Initiator trials were ∼50% more likely
to achieve clinical remission and 70%
more likely to achieve corticosteroid-free
remission compared with non-initiator
trials.
Figure 1 shows the cumulative proba-
bility of remission and corticosteroid-
free remission among the initiator and
non-initiator trials. The biologic treat-
ment effect emerged as early as 6
weeks of follow-up, which was when
the curves began to separate.
Analyses replacing the sPCDAI with
Physician Global Assessment of disease
severity produced a 26-week rate ratio
of 1.46 (95% CI, 1.16–1.85) for clinical
remission and 1.82 (95% CI, 1.41–2.35)
for corticosteroid-free remission, which
were similar to the estimates obtained
from the sPCDAI.
TABLE 1 Baseline Characteristics (ie, First Visit for Each Trial) for Anti-TNFa Initiator and Non-
Initiator Trials
Characteristic Initiator Trials Non-Initiator Trials P
% (95% CI)
Patient gender
Male 51.4 (44.9–57.9) 50.8 (45.9–55.8) .88
Female 48.6 (42.1–55.1) 49.2 (44.2–54.1)
Patient race
White 82.3 (77.1–87.4) 84.2 (80.7–87.7) .27
Black 13.6 (8.9–18.2) 10.2 (7.4–13.0)
Other 4.2 (1.4–6.9) 5.6 (3.3–7.9)
Disease phenotype
Inflammatory 89.0 (84.7–93.2) 87.1 (83.4–90.8) .63
Stricturing 3.9 (1.2–6.6) 5.4 (3.0–7.8)
Penetrating 7.1 (3.7–10.6) 7.5 (4.4–10.5)
Disease locations
Ileum 72.0 (66.1–77.8) 71.5 (66.9–76.0) .87
Colon 86.9 (82.5–91.2) 83.7 (80.2–87.1) .19
Upper tract 51.2 (44.7–57.7) 52.4 (47.4–57.4) .74
Medications
Thiopurine 33.8 (27.7–39.9) 59.6 (55.6–63.5) ,.01
Methotrexate 10.1 (6.2–13.9) 6.8 (4.8–8.8) .12
5-Aminosalicylate 35.3 (29.1–41.5) 49.5 (45.2–53.8) ,.01
Corticosteroid 27.2 (21.5–33.0) 43.4 (39.6–47.1) ,.01
Mean (95% CI)
Age (y) 14.9 (14.5–15.4) 14.6 (14.3–15.0) .24
Weight (kg) 51.3 (49.0–53.5) 49.9 (48.1–51.7) .30
Height (cm) 157.9 (155.6–160.2) 155.9 (154.0–157.8) .14
Disease duration (y) 2.8 (2.4–3.1) 2.7 (2.5–3.0) .75
sPCDAI score 41.9 (40.4–43.4) 41.1 (40.4–41.8) .36
Physician Global Assessment 2.7 (2.6–2.8) 2.4 (2.3–2.4) ,.01
C-reactive protein (mg/L)a 4.8 (3.2–6.4) 5.3 (4.1–6.4) .64
Erythrocyte sedimentation rate (mm/h)a 28.5 (25.2–31.9) 24.5 (22.6–26.5) .03
Albumin (g/dL)a 3.9 (3.8–3.9) 3.9 (3.9–4.0) .13
Hematocrit (%)a 36.1 (35.4–36.9) 36.9 (36.5–37.2) .07
a On average across the 100 replicates, C-reactive protein values were available for 54% of initiator and 50% of non-initiator
trials, erythrocyte sedimentation rate for 77% of initiator and 68% of non-initiator trials, albumin for 77% of initiator and 73%
of non-initiator trials, and hematocrit for 81% of initiator and 78% of non-initiator trials.
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On average across the 100 imputed
replicates, 110 initiator and 695 non-
initiator trials were right-censored
because they did not achieve re-
mission and did not have a visit at
6 months. We interpolated a sPCDAI
value at 26 weeks for these trials
and re-estimated the rate ratio for
remission, which was 1.54 (95% CI,
1.23–1.93).
There were an average of 159 initiator
and 897 non-initiator trials in the 100
imputed replicates for analyses that
involved a 26-week observation period
before trial initiation and 26-week
follow-up interval (ie, post-period). On
average, the chances of remission for
initiatorswere 32.6%higher in the post-
period compared with the pre-period,
whereas the post–pre change for
non-initiators was just 13.2%. The
difference-in-difference treatment ef-
fect estimate adjusts the change in the
initiator group for the change in the
non-initiator group and was 19.4%
(95% CI, 9.0–29.8) for clinical remis-
sion, an NNT of 5.2 (95% CI, 3.4–11.1).
The corticosteroid-free remission
difference-in-difference estimate was
19.9% (95% CI, 10.0–29.8) with an NNT
of 5.0 (95% CI, 3.4–10.0).
Contrast With REACH and SONIC
Applying REACH selection criteria4 to
the ICN sample yielded an average of 75
initiator trials across the 100 repli-
cates. The clinical response rates (to
be consistent with REACH, defined for
ICN as sPCDAI score ,30 and a mini-
mum decrease of 15) were: REACH 88%
(95% CI, 82%–94%)4 vs ICN 82% (95% CI,
72%–91%). The clinical remission rates
were: REACH 59% (95% CI, 50%–68%)4
vs ICN 49% (95% CI, 38%–61%).
Combining the infliximab-only with the
infliximab plus thiopurines treatment
arms from the SONIC trial6 yielded a 26-
week corticosteroid-free remission rate
of 51%, which contrasts with our
study’s estimate of 47%. The unadjusted
corticosteroid-free remission rate ratios
for the contrast with the comparison
groups were 1.69 (95% CI, 1.31–2.17)
for SONIC and 1.73 (95% CI, 1.38–2.16)
for ICN.
DISCUSSION
This study provides evidence that anti-
TNFa therapy given to pediatric patients
who have moderate to severe CD in real-
world settings is effective at achieving
remission at rates comparable to single-
group, open-label clinical trials, such as
REACH,4 with pediatric patients and
comparative controlled studies done
with adults, such as SONIC.6 The treat-
ment effect emerged as early as 6 weeks
after initiation of therapy. In our anal-
yses the outcome was achieved once
a visit satisfied either the clinical or
corticosteroid-free remission criteria,
even if subsequently the patient may
have experienced aworsening in disease
activity. Thus, our results provide evi-
dence on induction but not maintenance
of remission.
There are important differences be-
tween our observational study and
REACH and SONIC. Although we applied
the REACH selection criteria to initiator
trials, not all patients in our study were
assessed at 10 weeks; instead, we
allowed a patient to be assessed as late
as 16 weeks to account for variation in
visit frequency, which was at the dis-
cretion of patients and clinicians. Nei-
ther REACH nor our studyweremasked.
The SONIC study was done with an
adult sample, randomized and double-
blinded, and enrolled patients naïve to
thiopurines.
Like an open-labeled randomized trial,
the effect of treatment initiation in our
nonrandomized trials tests the combi-
nation of pharmacological and behav-
ioral effects induced by treatment
awareness among clinicians and par-
ticipants. Both patients and clinicians
TABLE 2 Percentage of Trials Achieving Remission and Corticosteroid-Free Remission During 26-
And 52-Week Follow-up Periods
Outcome Duration of Follow-up Initiator Trials Non-Initiator Trials
% Achieving Outcome (95% CI)
Unadjusted
Clinical remission 26 wk 54.4 (47.7–61.1) 41.2 (38.2–44.2)
52 wk 66.6 (60.3–72.8) 56.2 (53.2–59.3)
Corticosteroid-free remission 26 wk 47.3 (40.6–53.9) 31.2 (28.4–34.0)
52 wk 60.1 (53.7–66.5) 47.5 (44.5–50.5)
Adjusteda
Clinical remission 26 wk 54.8 (47.2–62.4) 40.7 (36.5–45.0)
52 wk 67.3 (60.1–74.4) 55.6 (51.1–60.1)
Corticosteroid-free remission 26 wk 45.6 (38.1–53.1) 30.8 (26.8–34.7)
52 wk 58.8 (51.5–66.2) 47.0 (42.5–51.5)
a Proportions were adjusted for patient age, gender, and race, disease location, duration, and phenotype, and concurrent
medications, all measured at baseline of the trial.
TABLE 3 Rate Ratios For Initiator Trials Versus Non-Initiator Trials at 10, 26, and 52 Weeks of
Follow-up




Initiator versus Non-Initiator Trials
Clinical remission 26 wk 1.44 (1.17–1.77) 1.53 (1.20–1.96)
52 wk 1.46 (1.22–1.74) 1.52 (1.23–1.89)
Corticosteroid-free
remission
26 wk 1.73 (1.38–2.16) 1.74 (1.33–2.29)
52 wk 1.63 (1.35–1.97) 1.62 (1.28–2.04)
a Rate ratios were adjusted for patient age, gender, and race, disease location, duration, and phenotype, and concurrent
medications, all measured at baseline of the trial.
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were aware of the decision to use bi-
ologic therapy. For this reason, we
preferred the use of the sPCDAI over the
Physician Global Assessment of disease
severity. The sPCDAI provided a more
objective assessment of disease activ-
ity, whereas the Physician Global As-
sessment may have been subject to
information bias, in which physicians
factored use of biologics into their
summary assessment of disease se-
verity. It was reassuring that analyses
using the Physician Global Assessment,
which had less missing data, produced
the same treatment effect estimates as
the sPCDAI.
As the demand for comparative effec-
tiveness evidence increases, new
strategies for estimating treatment
effects using observational data will be
needed. This is particularly true for
pediatrics, which frequently imports
results of adult studies into its evidence
base. The approach we used in this
study to examineobservational registry
data as a sequence of nonrandomized
trials is a promising methodology that
can be extended to other clinical
questions.28,29 The method allows gen-
eralization of likely benefits to patients
as it avoids overly strict selection cri-
teria that characterize explanatory
clinical trials, which test efficacy and
are not representative of real-world
practice.32
One of our biggest concerns regarding
the repurposing of the ICN registry data
for research was missing data. We used
MI, which assumes that data aremissing
at random and missingness is not in-
formative.26 This assumption may not
hold in our study, because it is possible
that clinicians were less likely to per-
form some examinations in patientswho
had low disease activity. The similarity in
treatment effects obtained with the
sPCDAI and Physician Global Assessment
of disease severity, which was present
for nearly every visit, was reassuring.
Unmeasured confounders, such as mu-
cosal inflammation observed by endos-
copy, may have positively influenced
both the decision to initiate treatment
and the level of disease activity; if this
were the case, biologic treatment effec-
tiveness would be underestimated. A fi-
nal limitation is the potential for bias
introduced by loss to follow-up. If this
occurred at a greater frequency among
anti-TNFa users in remission (less fre-
quent follow-up among patients doing
well) this would further underestimate
treatment effectiveness.
CONCLUSIONS
Our findings suggest that anti-TNFa
agents are comparatively more effec-
tive than usual care for treating chil-
dren who have moderate to severe CD
who are managed in routine clinical
practice settings. We have demon-
strated that prospectively collected
data from a large pediatric learning
health system can be used to answer
important clinical questions that can-
not be addressed with controlled trials
because of practical or ethical chal-
lenges. The study’s methodology offers
advantages relative to conventional
clinical trials in terms of time, cost,
recruitment, and the capacity to forgo
use of placebo. Our results are re-
markably consistent with those of
single-group efficacy studies among
FIGURE 1
Cumulative probability of remission and corticosteroid-free remission for initiator and non-initiator trials during a 26-week follow-up period.
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children4 and comparative controlled
clinical trials done among adults,4,6 but
they expand the evidence base by pro-
viding new information on the com-
parative effectives of anti-TNFa for CD
managed in routine pediatric gastro-
enterology settings.
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